Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors
Open Access
- 6 March 2007
- Vol. 109 (8), 1638-1645
- https://doi.org/10.1002/cncr.22587
Abstract
BACKGROUND. The Ewing sarcoma family of tumors (ESFT) is one of the most common malignant neoplasms of children and adolescents, characterized by nonrandom translocations involving the Ewing sarcoma (EWS) gene. Over the years the adoption of intensive multimodality treatment approaches has led to a gradual improvement in the survival of patients with ESFT. The prognosis is still unsatisfactory for high‐risk patients, however, and novel therapeutic approaches are desirable. The aim of the study was to investigate the expression/activation of KIT, PDGFRα, and PDGFRβ receptor tyrosine kinases (RTKs) as potential therapeutic targets in ESFT. METHODS. RNA and proteins were extracted from 20 frozen ESFT specimens to ascertain the state activation of KIT, PDGFRα, and PDGFRβ. RESULTS. No mutations were found, whereas the cognate ligands were detected in all cases by polymerase chain reaction (PCR). The expression and activation of KIT, PDGFRα, and PDGFRβ were confirmed by quantitative PCR, immunohistochemistry, and immunoprecipitation and/or Western blot analysis. In particular, when compared with a protein pool obtained from normal adult tissues, PDGFRβ showed a greater protein expression and/or a stronger phosphorylation signal. CONCLUSIONS. The results are consistent with an autocrine/paracrine loop activation of the KIT, PDGFRα, and PDGFRβ receptors and suggest a rationale for the use of RTK inhibitors, either alone or in combination with chemotherapy. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 36 references indexed in Scilit:
- Molecularly confirmed primary malignant rhabdoid tumor of the urinary bladder: implications of accurate diagnosisAnnals of Diagnostic Pathology, 2012
- Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study groupPediatric Blood & Cancer, 2010
- The tyrosine kinase c‐Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumorsCancer, 2010
- Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumorsPediatric Blood & Cancer, 2009
- Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patientBritish Journal of Cancer, 2007
- 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized forc-kit and platelet-derived growth factor receptor α gene alterationsCancer, 2005
- Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced ApoptosisClinical Cancer Research, 2004
- c-kit Receptor Expression in Ewing’s Sarcoma: Lack of Prognostic Value but Therapeutic Targeting Opportunities in Appropriate ConditionsJournal of Clinical Oncology, 2003
- Potential Use of Imatinib in Ewing's Sarcoma: Evidence for In Vitro and In Vivo ActivityJNCI Journal of the National Cancer Institute, 2002
- Rhabdoid Tumor of the Kidney in an Adult: Review of the Literature and Report of a Case Responding to Interleukin-2Cancer Biotherapy, 1995